Related Experiment Videos
Serum laminin in Graves' disease
European Journal of Clinical Investigation
|June 1, 1995
Summary
Serum laminin levels are significantly elevated in Graves' disease (GD) patients before treatment. These levels decrease with thiamazole therapy, suggesting laminin may indicate extracellular matrix changes in GD.
Area of Science:
- Endocrinology
- Biochemistry
- Pathology
Background:
- Graves' disease (GD) is an autoimmune disorder characterized by hyperthyroidism.
- Thyroid extracellular matrix (ECM) remodeling is implicated in GD pathogenesis.
- Laminin, a key basement membrane component, is a potential biomarker for ECM alterations.
Purpose of the Study:
- To investigate serum laminin levels in patients with Graves' disease (GD) and toxic nodular goiter (TNG).
- To assess the effect of thiamazole treatment on serum laminin levels in GD patients.
- To explore the relationship between serum laminin and thyroid hormone levels or autoantibodies.
Main Methods:
- Serum samples were collected from 23 GD patients, 24 TNG patients, and 26 healthy controls.
- Serum laminin concentrations were quantified using a validated assay.
- GD patients were followed during thiamazole treatment for up to 8 weeks.
Main Results:
- Significantly elevated serum laminin levels were found in GD patients (median 1376 ng/mL) compared to TNG patients (median 442 ng/mL) and controls (median 492 ng/mL).
- Serum laminin levels in GD patients decreased during thiamazole treatment, normalizing within 8 weeks.
- No correlation was observed between serum laminin levels and thyroid hormones or autoantibodies in GD patients.
Conclusions:
- Elevated serum laminin may serve as a biomarker for extracellular matrix alterations in Graves' disease.
- Thiamazole treatment effectively reduces serum laminin levels in GD patients.
- Further research is needed to clarify the role of serum laminin in GD pathogenesis and clearance mechanisms.